Augusta University

augusta.edu

Total trials

179

Active

26

Phase 3

9

Total enrollment

66,001

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 10 of 10 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Olanzapine3
Single Agent Asciminib1
Low TKI1
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone1
Candesartan1
Resveratrol1
Genetic Testing for hematological malignancies1
Antifungal treatment1
NMD; 0.4mg sub-lingual nitroglycerin spray1
Bosentan1

Next readouts

  • 2025-12
  • 2025-12
  • 2026-12
  • 2027-01-01
  • 2027-05-01
  • 2027-10
  • 2027-11-01
  • 2029-02
  • 2032-02

Top conditions

  • Cardiovascular Diseases10
  • Hypertension10
  • Obesity10
  • Constipation9
  • Heart Diseases5
  • Blood Pressure5
  • Fecal Incontinence5
  • Cystic Fibrosis4

Frequently asked questions about Augusta University

How many clinical trials does Augusta University have on ClinicalTrials.gov?
Augusta University is listed as the lead sponsor on 179 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
How many of Augusta University's trials are in Phase 3?
9 of Augusta University's trials are in Phase 3, spread across 10 active drug programs.
What therapeutic areas does Augusta University focus on?
Augusta University's most-studied conditions on ClinicalTrials.gov are Cardiovascular Diseases, Hypertension, Obesity, Constipation, Heart Diseases.
When are Augusta University's next clinical trial readouts?
Augusta University has 9 upcoming primary-completion readouts tracked here; the soonest is “Endothelin Receptor Function and Acute Stress”, expected around 2025-12.